Abstracts

THE ANCIENT AND MODERN ORIGINS OF HIV

How did HIV-1 become a human pathogen? In this talk, I will trace the origins of HIV-1 through the cross-species transmissions and viral adaptations that preceded its emergence in humans. The immediate precursor of HIV-1 is a virus that infects chimpanzees, Simian Immunodeficiency Virus of Chimpanzees (SIVcpz). SIVcpz is itself derived from other SIV lineages…

HIV CURE FROM BENCH TO BEDSIDE

Despite the great success of antiviral therapy (ART), treatment is life long for the majority of people living with HIV (PLWH). Antiviral treatment is simple and relatively cheap and close to 60% of PLWH have access to treatment. However, ART is still not available or secure for many, drug resistance is common globally and there…

UNIVERSAL TEST AND TREAT (UTT): LESSONS FROM THE PAST AND FOR THE FUTURE

This presentation discusses the four recently completed community randomized trials of “Universal Test and Treat” (UTT) in East and southern Africa and their implications. Three themes developed in parallel and led to these ambitious implementation studies: recognition of the centrality of viral load for HIV pathogenesis and HIV transmission; studies showing >90% effectiveness of “treatment…

NONALCOHOLIC STEATOHEPATITIS

Non-alcoholic fatty liver disease (NAFLD) impacts affecting 25% of adults worldwide. NAFLD is a spectrum of pathology including steatosis and non-alcoholic steatohepatitis (NASH), the progressive form of NASH which can lead to fibrosis development, cirrhosis, end-stage liver disease, and hepatocellular carcinoma. NASH cirrhosis is the second leading indication for liver transplantation in the United States. In addition, NAFLD is strongly associated…

WHEN AT THIRD YOU DON’T SUCCEED

Current HCV direct acting antiviral (DAA) regimens are highly efficacious; including in populations previously recognized to have poor responses to interferon-based therapies (e.g. HIV co-infection, cirrhosis etc.). However, as DAAs are used in a greater number of patients in clinical practice, scenarios which have not been adequately addressed in clinical trials, or are impractical to…

NONINFERIORITY COMPLEX

In general, active-controlled noninferiority (NI) trials are considered when superiority trials, to an active control or placebo, are not possible due to ethical or other considerations. NI trials share some of the same biases as historically controlled trials because they rely on information external to the clinical trial. Food and Drug Administration (FDA) guidance states that NI…

INCLUSION OF DIVERSE POPULATIONS IN TRIALS

The unprecedented nature of AIDS as a syndrome and a pandemic created unprecedented demands on clinical trials investigators and networks to creatively and meaningfully address the syndromic nature of AIDS, the complex etiology and pathogenesis of HIV infection, its associated opportunistic infections, coinfections, and malignant, end-organ, and neurologic sequelae, in diverse affected populations including men…